12 Nov 2024 by admin in UncategorizedComments Zenas BioPharma Completes Targeted Enrolment of the Phase 3 INDIGO Trial of Obexelimab in Imunoglobulin G4-Related Disease (IgG4-RD) in Immunoglobulin G4-Related Disease (IgG4-RD)
12 Nov 2024 by admin in UncategorizedComments Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
10 Nov 2024 by admin in UncategorizedComments Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
23 Oct 2024 by admin in UncategorizedComments Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies
16 Oct 2024 by admin in UncategorizedComments Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
30 Sep 2024 by admin in UncategorizedComments Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
18 Sep 2024 by admin in UncategorizedComments Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
10 Sep 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces Formation of Scientific Advisory Board
03 Sep 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer
